Navigation Links
Occlutech and IZASA Obtains Favourable Ruling in Proceeding Initiated by AGA Medical in Spain
Date:9/21/2009

ZURICH, September 21 /PRNewswire/ -- Occlutech AG, the leading European developer of products for septal closure, today announced that, together with its partner in Spain IZASA SA, it defeated a request for an injunction against sales and marketing activities in Spain, launched at the Commercial Court I of Barcelona, Spain by its U.S. competitor AGA Medical.

The request by AGA was based on alleged patent infringement and unfair competition claims related to wrongful assumptions and misleading statements about the outcome of a recent ruling by the patent court in Dusseldorf and about Occlutech.

The Court came to the conclusion that Occlutech's products offered for sale by IZASA do not infringe patent EP0808138 held by AGA in Spain that is Europe's fifth largest market.

Further in October 2008 Occlutech won against AGA Medical in the District Court of The Hague. In December 2008 the Higher Regional appeal Court in Dusseldorf, that has no jurisdiction over sales by Occlutech's partners outside of Germany, decided against Occlutech. In July 2009, however, the Patents Court of the High Court of Justice, London declared that Occlutech's products are not infringing AGA's patent EP 0808138.

Above Court decisions are not final and subject to appeal that are/can be filed by AGA or Occlutech.

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.


'/>"/>
SOURCE Occlutech AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
2. AGA Medical to Appeal Ruling by Dutch Court in Lawsuit With Occlutech GmbH
3. AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
4. Occlutech Obtains CE Mark for the new Generation PFO & ASD Occluders
5. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
6. Patient Lift Manufacturer, Medcare Products, Obtains Women-Owned Certification
7. Aspreva obtains shareholder approval for acquisition by Galenica
8. VIE Healthcare Expands Its Operations in the Midwest, and Obtains First Local Client
9. DRAXIS Obtains Interim Order for Proposed Arrangement
10. DRAXIS Obtains Final Order for Proposed Arrangement
11. China Medicine Corporation Obtains Australian Patent for rADTZ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: